美股異動丨極光盤前漲約2% 受益英偉達H20芯片將恢復在華銷售
中國領先的客戶互動與營銷科技服務商極光(JG.US)盤前漲約2%。消息上,近日,英偉達宣佈恢復H20芯片對中國市場的銷售,極光迎來重要發展契機。此次芯片恢復供應,正值極光旗下AI智能體平臺GPTBots.ai在全球市場快速增長之際。極光董事長兼首席執行官羅偉東先生表示:"英偉達H20芯片恢復在華銷售將有力促進GPTBots.ai的發展。業界對我們AI智能體平臺的需求強勁。藉助該芯片的算力提升,GPTBots.ai將不僅滿足客戶需求、更將超越客戶預期。這標誌着我們向‘全球領先的企業級AI解決方案提供商’目標邁出了重要一步。"(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.